S2 Ep23: Diving Into the Safety and Efficacy of Icotrokinra, the New Oral IL-23 Peptide in Psoriasis

S2 Ep23: Diving Into the Safety and Efficacy of Icotrokinra, the New Oral IL-23 Peptide in Psoriasis

From The Cutaneous Connection by The Cutaneous Connection

May 1, 2026 · 10 min · Season 2 · Episode 23

About this episode

Dr. Liza O'Dowd discusses the safety and efficacy of icotrokinra for treating psoriasis.

Join Dermatology Times for a conversation with Liza O'Dowd, MD, vice president of immunodermatology and respiratory disease areas at Johnson & Johnson, recorded at the 2026 AAD Annual Meeting. Dr. O'Dowd discusses one-year efficacy and safety data for icotrokinra (Icotyde), the newly approved once-daily oral peptide IL-23 receptor antagonist for moderate to severe plaque psoriasis in adults and adolescents 12 and older. At 52 weeks, approximately 50% of adult patients achieved total skin clearance, rising to 60% in adolescents enrolled in the LEAD study. Adverse event rates through one year remained within 1.1% of placebo, with no mandatory tuberculosis pre-screening required. Dr. O'Dowd also addresses icotrokinra's anticipated role as a first-line systemic therapy and offers practical reassurance for clinicians considering this novel agent for their patients. For more content from Dermatology Times, visit https://www.dermatologytimes.com/

People in this episode

Guests: Liza O'Dowd, MD, Liza O'Dowd

Topics covered

  • psoriasis
  • dermatology
  • clinical trials
  • immunotherapy
  • healthcare

Keywords

  • icotrokinra
  • psoriasis
  • IL-23
  • clinical efficacy
  • adverse events

Mentioned in this episode

Organizations: Johnson & Johnson

Products: icotrokinra, Icotyde

Places: United States

More episodes of The Cutaneous Connection

Explore listener stats, chart rankings, contacts and more on the The Cutaneous Connection podcast page.